



Targeted Therapy of Melanoma: Novel Mechanisms and Biomarkers of Drug Resistance

Guest Editors:

Dr. Francesco Facchiano

Department of Oncology and
Molecular Medicine, Istituto
Superiore di Sanità, Viale Regina
Elena 299, 00161 Rome, Italy

Dr. Claudio Tabolacci

Department of Oncology and
Molecular Medicine, Istituto
Superiore di Sanità, Viale Regina
Elena 299, 00161 Rome, Italy

Dr. Stefania D'Atri

Molecular Oncology Laboratory,
Istituto Dermopatico
dell'Immacolata IRI-IRCCS, 00167
Rome, Italy

Message from the Guest Editors

Melanoma is an aggressive cutaneous cancer that causes the greatest number of skin-cancer-related deaths worldwide. While early-stage melanoma can be cured successfully by surgical resection, stage IV melanoma has a dismal prognosis and is almost completely resistant to conventional chemotherapy and radiotherapy.

The aim of the present Special Issue is to create a collection of studies focused on the identification of new molecular mechanisms and biomarkers of drug resistance to molecularly targeted drugs used or under investigation to underline the current state of the art in these new promising weapons against cutaneous melanoma.

Deadline for manuscript
submissions:

closed (30 June 2023)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)